Zusammenfassung
GRUNDLAGEN: Bei Patienten mit fortgeschrittener Krebserkrankung ist Dyspnoe eines der häufigsten Symptome. Opioide zählen mit zur Standardtherapie. ZIEL: Ziel der Studie war, den Wissenstand von Studenten im 8. Semester über Diagnose und Therapiemaßnahmen von Dyspnoe zu evaluieren. METHODIK: Ein Fallbericht eines Patienten mit akuter Dyspnoe bei fortgeschrittenem Bronchialkarzinom wurde an Studenten verteilt mit der Bitte, diagnostische und therapeutische Optionen nach einem Rankingsystem anzugeben. ERGEBNISSE: 633 Medizinstudenten erhielten einen Fallbericht, dieser wurde von 423 vollständig ausgefüllt. Die häufigste diagnostische Maßnahme war die Messung der Sauerstoffsättigung mittels Pulsoxymeter (n = 388), gefolgt von Auskultation (n = 339). Die häufigste Behandlungsoption für Studenten war die Verabreichung von Sauerstoff (n = 393). Immerhin 138 Studenten schlugen die Verabreichung von Opioiden vor. SCHLUSSFOLGERUNGEN: Obwohl die Studenten über wenig praktische Erfahrung verfügten, schlugen 32,6% eine Behandlung mit Opioiden vor.
Summary
BACKGROUND: Dyspnea is common in advanced cancer patients with opioids as first line treatment. OBJECTIVES: To evaluate the level of knowledge about diagnosis and treatment of dyspnea in palliative care patients among 4th year students. METHODS: A case report was distributed to the students describing acute dyspnea in a lung cancer patient. Students were asked to rank their diagnosis and treatment options by importance. RESULTS: 633 medical students in their 4th year attended a seminar about palliative care. Of these, 423 (77%) completed the case report. The most frequent diagnostic option was measuring patient's oxygen saturation (n = 388), followed by auscultation (n = 339). As treatment options, students chose the delivery of oxygen (n = 393) as most important. The application of opioids was suggested by a total of 138 students. CONCLUSION: Although students did not have practical skills in treating advanced cancer patients with acute dyspnea, 32.6% would suggest an opioid as treatment option.
References
Bruera E, Schmitz B, Pither J, et al. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage, 19: 357–362, 2000
Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest, 89: 234–236, 1986
Curtis EB, Krech R, Walsh TD. Common symptoms in patients with advanced cancer. J Palliat Care, 7: 25–29, 1991
Dudgeon DJ, Kristjanson L, Sloan JA, et al. Dyspnea in cancer patients: prevalence and associated factors. J Pain Symptom Manage, 21: 95–102, 2001
Higginson I, McCarthy M. Measuring symptoms in terminal cancer: are pain and dyspnoea controlled? J R Soc Med, 82: 264–267, 1989
Conill C, Verger E, Henriquez I, et al. Symptom prevalence in the last week of life. J Pain Symptom Manage, 14: 328–331, 1997
Mercadante S, Casuccio A, Fulfaro F. The course of symptom frequency and intensity in advanced cancer patients followed at home. J Pain Symptom Manage, 20: 104–112, 2000
Simon ST, Bausewein C. Management of refractory breathlessness in patients with advanced cancer. Wien Med Wochenschr, 159: 591–598, 2009
Viola R, Kiteley C, Lloyd NS, et al. The management of dyspnea in cancer patients: a systematic review. Support Care Cancer, 16: 329–337, 2008
Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax, 57: 939–944, 2002
Chan KSMTDTA. Palliative medicine in malignant respiratory diseases. In: Doyle D GHNCKC (ed) Oxford textbook of palliative medicine. Third edition. Oxford University Press, 2005.
Kin-Sang Chan DMWTMMKS&ABT. Palliative medicine in malignant respiratory diseases. In: Geoffrey Hanks NICNACMFSKaRKP (ed) Oxford textbook of palliative medicine. Fourth edition. Oxford University Press, 2009.
Corner J, Plant H, A'Hern R, Bailey C. Non-pharmacological intervention for breathlessness in lung cancer. Palliat Med, 10: 299–305, 1996
Bausewein C, Booth S, Gysels M, Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev, 2008(2): 16, 2008
Kemp C. Palliative care for respiratory problems in terminal illness. Am J Hosp Palliat Care, 14: 26–30, 1997
Pan CX, Morrison RS, Ness J, et al. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manage, 20: 374–387, 2000
Thomas JR, Von Gunten CF. Clinical management of dyspnoea. Lancet Oncol, 3: 223–228, 2002
Bruera E, de Stoutz N, Velasco-Leiva A, Schoeller T, Hanson J. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet, 342(8862): 13–14, 1993
Bruera E, MacEachern T, Ripamonti C, Hanson J. Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med, 119: 906–907, 1993
Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev 2010(1): 20, 2010
Thomas JR, Von Gunten CF. Management of dyspnea. J Support Oncol, 1: 23–32, 2003
Davis CL. ABC of palliative care. Breathlessness, cough, and other respiratory problems. BMJ, 315(7113): 931–934, 1997
Del Fabbro E, Dalal S, Bruera E. Symptom control in palliative care – Part III: dyspnea and delirium. J Palliat Med, 9: 422–436, 2006
Batchelor TT, Taylor LP, Thaler HT, et al. Steroid myopathy in cancer patients. Neurology, 48: 1234–1238, 1997
Croxton TL, Weinmann GG, Senior RM, et al. Clinical research in chronic obstructive pulmonary disease: needs and opportunities. Am J Respir Crit Care Med, 167: 1142–1149, 2003
Congleton J, Muers MF. The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy. Respir Med, 89: 291–296, 1995
Kauser F, LeGrand SB. Theophylline for unexplained dyspnea in palliative medicine: a case report. J Palliat Med, 11: 510–513, 2008
Cachia E, Ahmedzai SH. Breathlessness in cancer patients. Eur J Cancer, 44: 1116–1123, 2008
Dudgeon DJ, Lertzman M, Askew GR. Physiological changes and clinical correlations of dyspnea in cancer outpatients. J Pain Symptom Manage, 21: 373–379, 2001
Bruera E, Schoeller T, MacEachern T. Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: the use of the N of 1 randomized controlled trial. J Pain Symptom Manage, 7: 365–368, 1992
Cranston JM, Crockett A, Currow D. Oxygen therapy for dyspnoea in adults. Cochrane Database Syst Rev, 2008(3): 16, 2008
Uronis HE, Abernethy AP. Oxygen for relief of dyspnea: what is the evidence? Curr Opin Support Palliat Care, 2: 89–94, 2008
Bruera E, Macmillan K, Pither J, MacDonald RN. Effects of morphine on the dyspnea of terminal cancer patients. J Pain Symptom Manage, 5: 341–344, 1990
Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med, 159: 321–340, 1999
Ben Aharon I, Gafter-Gvili A, Paul M, et al. Interventions for alleviating cancer-related dyspnea: a systematic review. J Clin Oncol, 26: 2396–2404, 2008
Currow DC, Smith J, Davidson PM, et al. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. J Pain Symptom Manage, 39: 680–690, 2010
Boyd KJ, Kelly M. Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer. Palliat Med, 11: 277–281, 1997
Cohen MH, Anderson AJ, Krasnow SH, et al. Continuous intravenous infusion of morphine for severe dyspnea. South Med J, 84: 229–234, 1991
Ventafridda V, Ripamonti C, De Conno F, et al. Symptom prevalence and control during cancer patients' last days of life. J Palliat Care, 6: 7–11, 1990
Zeppetella G. Nebulized morphine in the palliation of dyspnoea. Palliat Med, 11: 267–275, 1997
Booth S, Kelly MJ, Cox NP, et al. Does oxygen help dyspnea in patients with cancer? Am J Respir Crit Care Med, 153: 1515–1518, 1996
Clemens KE, Quednau I, Klaschik E. Is there a higher risk of respiratory depression in opioid-naive palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliat Med, 11: 204–216, 2008
Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ, 327(7414): 523–528, 2003
Borasio GD, Weltermann B, Voltz R, et al. Attitudes towards patient care at the end of life. A survey of directors of neurological departments. Nervenarzt, 75: 1187–1193, 2004
Bendiane MK, Peretti-Watel P, Pegliasco H, et al. Morphine prescription to terminally ill patients with lung cancer and dyspnea: French physicians' attitudes. J Opioid Manag, 1: 25–30, 2005
Navigante AH, Cerchietti LC, Castro MA, et al. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage, 31: 38–47, 2006
Navigante AH, Castro MA, Cerchietti LC. Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. J Pain Symptom Manage, 39: 820–830, 2010
Rigg JR. Ventilatory effects and plasma concentration of morphine in man. Br J Anaesth, 50: 759–765, 1978
LeGrand SB, Khawam EA, Walsh D, Rivera NI. Opioids, respiratory function, and dyspnea. Am J Hosp Palliat Care, 20: 57–61, 2003
Walsh TD. Opiates and respiratory function in advanced cancer. Recent Results Cancer Res, 89: 115–117, 1984
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pohl, G., Marosi, C., Dieckmann, K. et al. Evaluation of diagnostic and treatment approaches towards acute dyspnea in a palliative care setting among medical students at the University of Vienna. Wien Med Wochenschr 162, 18–28 (2012). https://doi.org/10.1007/s10354-011-0046-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10354-011-0046-z